Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Atripla - HHS HIV guidelines panel / ClinicalInfo
Product / population
Adults or adolescents with HIV taking the efavirenz/emtricitabine/TDF fixed-dose tablet.
Renal method
Adult CrCl in mL/min; panel has a separate hemodialysis entry.
Source revision
Online guidance checked 2026-11-07; section revision not established.
HHS HIV guidelines panel / ClinicalInfo · Adults or adolescents with HIV taking the efavirenz/emtricitabine/TDF fixed-dose tablet.
Renal method: Adult CrCl in mL/min; panel has a separate hemodialysis entry. Source date: Online guidance checked 2026-11-07; section revision not established. Retrieved: 2026-11-07
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
The panel advises avoiding TDF when possible below CrCl 60 mL/min. This efavirenz/emtricitabine/TDF fixed combination is not recommended below 50 mL/min or on HD. The ingredient-level TDF interval must not be applied to the fixed tablet.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
